Improving the management and reducing the transmission of drug resistant tuberculosis in the UK

Project Details

Description

PROJECT SUMMARY
The 'rising tide' of antimicrobial resistance is a source of concern across most infectious diseases. In the UK, for example, 6.8% of the ~8,500 tuberculosis cases seen in 2012 were resistant to the cheap and effective first-line drug isoniazid. It is of vital importance to prevent the loss of current anti-tuberculosis drugs. This Fellowship aims to inform clinical knowledge and policy surrounding drug resistant cases, thus improving case management and reducing transmission, by a) determining the effectiveness of different regimens for resistant cases and b) exploring microbiological and clinical markers that could be rapidly adopted as predictors of treatment success.

SYSTEMATIC REVIEWS AND NETWORK META-ANALYSIS
These systematic reviews and network meta-analysis aimed to assess the efficacy of different treatment regimens for active tuberculosis patients with drug resistant (but not multidrug resistant) disease. They were registered on the PROSPERO system as CRD42014015025.

COHORT STUDY
Study design: This cohort study compared the relative effectiveness of different treatment regimens for active tuberculosis patients with drug resistant (but not multidrug resistant) disease. It was registered on clinicaltrials.gov as Z6364106/2016/04/28.
AcronymDR-TB in the UK
StatusFinished
Effective start/end date1/01/1531/12/17

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.